By Digifin Pty Ltd · About this coverage
Key Points
- Gedeon Richter to acquire Mayne Pharma for A$6.40 cash per share by scheme
- Values equity at approximately A$604 million, a 99.4% premium to the 16 November close
- Board unanimously recommends the Scheme, subject to the Independent Expert and no Superior Proposal
- Conditional on FIRB, Hart-Scott-Rodino, Court approval and the Evaris Pharma sale
- Scheme Meeting expected in late January and implementation in March

About Mayne Pharma (ASX:MYX)
Mayne Pharma Group Limited is an ASX-listed specialty pharmaceutical company headquartered in Adelaide. It commercialises dermatology and women's health medicines, primarily in the United States, and operates a direct-to-patient prescription distribution platform through its licensed pharmacy, Adelaide Apothecary. The company also provides contract development and manufacturing services to clients worldwide.
Mayne Pharma (ASX:MYX) has entered a Scheme Implementation Deed with Gedeon Richter Plc, under which Richter has agreed to acquire 100% of Mayne Pharma's shares for A$6.40 cash per share by scheme of arrangement.
The Scheme Consideration values Mayne Pharma's equity at approximately A$604 million, which the company calculates on about 94.4 million shares assuming its Convertible Notes convert at maturity. It represents a premium of 99.4% to the closing share price on 16 November 2026 and 124% to the 30-day VWAP. The Board unanimously recommends shareholders vote in favour, in the absence of a Superior Proposal and subject to the Independent Expert concluding that the Scheme is in their best interests. Funicular Funds (9.82%), Mr Bruce Mathieson (6.46%) and Trium Capital (5.85%), together holding 22.14%, have each said they intend to vote in favour absent a Superior Proposal. Richter will fund the acquisition from internal cash resources and there is no financing condition. Conditions include Foreign Investment Review Board and Hart-Scott-Rodino approvals, shareholder and Court approval, and completion of the sale of the International business to Evaris Pharma, which is itself subject to ACCC approval. The parties will also file a voluntary CFIUS declaration. The Scheme Meeting is expected in late January and implementation in March.
The timetable is indicative. Regulatory approvals, the Independent Expert's report, shareholder and Court approval, and the International business sale are all outstanding. Break fee terms are left to the attached deed.
Source: Mayne Pharma Group Limited (ASX:MYX), 17 November 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.
